Price movement over the last 24 hours
AbbVie Inc vs eBay Inc — how do they compare? AbbVie Inc trades at $253.82 (market cap $449.91B), while eBay Inc trades at $114.53 (market cap $50.94B). The key difference: AbbVie Inc is far larger — about 8.8× eBay Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | EBAY | |
|---|---|---|
Market Cap | $449.91B | $50.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $118.96 |
52-Week Low | $184.85 | $75.33 |
Enterprise Value | $513.38B | $54.28B |
Dividend Yield | 2.72% | 1.08% |
Volume | — | 5,186,418 |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
EBAY trades at $114.71, down slightly by 0.11% today. The stock shows strong profitability with a 17.61% net income margin and has beaten earnings estimates for three consecutive quarters. Technical indicators are bullish, with the price above key moving averages. Recent news highlights GameStop's unsolicited takeover interest, adding speculative momentum. Cash flow turned negative in 2025 but is projected to recover in 2026.
The outlook is mixed: solid fundamentals and earnings beats support upside, but the stock trades above the analyst consensus target of $109.50. Risks include takeover uncertainty and competitive pressures. Wall Street sentiment is neutral with a slight buy bias, though valuation multiples like P/E of 26.25 suggest limited near-term growth potential.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →